VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB
ACE-CL-311 (AMPLIFY)
Phase 3 small_molecule active
Quick answer
VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB for Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active